Department of Cell Biology
The fragile X syndrome (FXS) is the most frequent inherited form of intellectual disability, and often associated with emotional disorders such as autism and anxiety. Currently, we are investigating whether PI3K inhibitors and/or p110β antagonists can reverse synaptic and behavioral phenotypes in FXS mice. Our current findings suggest that targeting PI3K, which is currently used to treat cancer, might also be a promising therapy for FXS and other ASDs.
View publications on PubMed